title: Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women.
abstract: CONCLUSIONS
  We developed and validated a specific 12-item questionnaire to evaluate adherence to oral antiresorptive medication by post-menopausal osteoporotic women in everyday practice. Over the following 9 months, an index of ≤16 was associated with an increase in the risk of treatment discontinuation of 1.69 and of 2.10 for new patients who had started treatment within the previous year.
  
  
  BACKGROUND
  Adherence to medication in osteoporosis is poor. The goal of this study was to develop and validate a disease-specific questionnaire to evaluate adherence to treatment of women with post-menopausal osteoporosis taking oral antiresorptive medication.
  
  
  METHODS
  A prototype adherence questionnaire with 45 items developed from patient interview, literature review, and physician opinion was evaluated in a sample of 350 post-menopausal women with osteoporosis treated in primary care. Item responses were matched against scores on the Morisky Medication Adherence Scale (MMAS). The most discriminant items were retained in the final questionnaire. Concurrent and predictive validity were assessed.
  
  
  RESULTS
  Twelve items were associated with MMAS score at a probability level of 0.05. These were retained in the final questionnaire which provided an adherence index ranging from 0 to 22. An index of ≥20 was associated with a high probability of persistence and an index ≤ 16 with a high probability of treatment discontinuation in the following 9 months.
  
  
  CONCLUSIONS
  The ADEOS-12 is a simple patient-reported measure to determine adherence to osteoporosis treatments with good concurrent and discriminant validity. This is the first disease-specific adherence measure to have been developed for osteoporosis.
authors.affiliation: Rheumatology Department, Nice University Hospital, Nice, France.
authors.forename: V
authors.initials: V
authors.lastname: Breuil
authors.forename: B
authors.initials: B
authors.lastname: Cortet
authors.forename: F-E
authors.initials: FE
authors.lastname: Cotté
authors.forename: B
authors.initials: B
authors.lastname: Arnould
authors.forename: C
authors.initials: C
authors.lastname: Dias-Barbosa
authors.forename: A-F
authors.initials: AF
authors.lastname: Gaudin
authors.forename: A
authors.initials: A
authors.lastname: Regnault
authors.forename: A
authors.initials: A
authors.lastname: Roborel de Climens
authors.forename: E
authors.initials: E
authors.lastname: Legrand
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001294:Attitude to Health; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D055118:Medication Adherence; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000523:psychology; D011594:Psychometrics; D011795:Surveys and Questionnaires
chemical_list: D050071:Bone Density Conservation Agents